Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
CD22 expression
i
Other names:
CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
933
Related biomarkers:
Expression
‹
›
Associations
(3)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (NCT05442515)
Phase 1/2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/14/2024
Initiation :
12/28/2022
Primary completion :
07/01/2027
Completion :
07/01/2029
CD19 • CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (A041703) (NCT03739814)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/13/2024
Initiation :
05/08/2019
Primary completion :
02/01/2025
Completion :
02/01/2025
ABL1 • BCR • CD22
|
CD22 positive • CD22 expression
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (NCT03448393)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/06/2024
Initiation :
03/26/2018
Primary completion :
12/01/2025
Completion :
12/31/2040
CD19 • CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells • cyclophosphamide intravenous
Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies (NCT02315612)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 1
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
06/05/2024
Initiation :
12/12/2014
Primary completion :
04/03/2019
Completion :
06/01/2040
CD22
|
CD22 expression
|
JCAR018 • anti-CD22 CAR T
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant (NCT04815356)
Phase 1
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
05/23/2022
Primary completion :
12/01/2036
Completion :
12/01/2036
CD22
|
CD22 expression
|
cyclophosphamide • JCAR018 • anti-CD22 CAR T
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (AALL1621) (NCT02981628)
Phase 2
Children's Oncology Group
Children's Oncology Group
Recruiting
Phase 2
Children's Oncology Group
Recruiting
Last update posted :
05/30/2024
Initiation :
06/19/2017
Primary completion :
03/31/2026
Completion :
03/31/2026
KMT2A • CD22
|
MLL rearrangement • CD22 expression
|
cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
CART22 Alone or in Combination With huCART19 for ALL (NCT03620058)
Phase 1
University of Pennsylvania
University of Pennsylvania
Active, not recruiting
Phase 1
University of Pennsylvania
Active, not recruiting
Last update posted :
05/24/2024
Initiation :
09/27/2018
Primary completion :
01/01/2036
Completion :
01/01/2036
CD22
|
CD22 expression
|
CART22 • huCART19
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (AALL0434) (NCT00408005)
Phase 3
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/23/2024
Initiation :
01/22/2007
Primary completion :
09/30/2017
Completion :
03/07/2025
CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO
|
CD22 expression
|
cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • nelarabine • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (NCI-2018-02016) (NCT03698552)
Phase 1/2
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Recruiting
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
05/15/2024
Initiation :
08/24/2018
Primary completion :
12/31/2025
Completion :
12/31/2025
CD22
|
CD22 expression
|
epratuzumab-cys-tesirine (ADCT-602)
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia (NCT03913559)
Phase 2
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Recruiting
Phase 2
St. Jude Children's Research Hospital
Recruiting
Last update posted :
04/19/2024
Initiation :
05/14/2019
Primary completion :
12/01/2024
Completion :
01/01/2025
CD22
|
CD22 expression
|
cytarabine • methotrexate • Besponsa (inotuzumab ozogamicin) • methylprednisolone sodium succinate
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (AALL1231) (NCT02112916)
Phase 3
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/22/2024
Initiation :
10/04/2014
Primary completion :
03/31/2020
Completion :
09/22/2024
CD20 • CD8 • CD22 • CD34 • CD5 • CD7 • CD2 • MPO
|
CD22 expression
|
cytarabine • bortezomib • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (IRB-50836) (NCT04088890)
Phase 1
Stanford University
Stanford University
Active, not recruiting
Phase 1
Stanford University
Active, not recruiting
Last update posted :
03/07/2024
Initiation :
09/12/2019
Primary completion :
12/30/2024
Completion :
12/30/2037
CD22
|
CD22 positive • CD22 expression • CD20 negative
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies (NCT03233854)
Phase 1
Crystal Mackall, MD
Crystal Mackall, MD
Active, not recruiting
Phase 1
Crystal Mackall, MD
Active, not recruiting
Last update posted :
02/28/2024
Initiation :
09/01/2017
Primary completion :
09/01/2025
Completion :
09/01/2035
CD19 • CD22
|
CD19 positive • CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV • avipendekin pegol (NKTR-255) • cyclophosphamide intravenous
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies (NCT04088864)
Phase 1
Stanford University
Stanford University
Active, not recruiting
Phase 1
Stanford University
Active, not recruiting
Last update posted :
02/12/2024
Initiation :
01/10/2020
Primary completion :
10/31/2023
Completion :
09/10/2036
CD22
|
CD22 positive • CD22 expression
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)
International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 (IntReALL SR 2010) (NCT01802814)
Phase 3
Charite University, Berlin, Germany
Charite University, Berlin, Germany
Completed
Phase 3
Charite University, Berlin, Germany
Completed
Last update posted :
02/09/2024
Initiation :
05/01/2014
Primary completion :
07/31/2023
Completion :
07/31/2023
CD22
|
CD22 expression
|
Epratucyn (epratuzumab)
CD22 Redirected Autologous T Cells for ALL (NCT02650414)
Phase 1
University of Pennsylvania
University of Pennsylvania
Recruiting
Phase 1
University of Pennsylvania
Recruiting
Last update posted :
02/05/2024
Initiation :
01/13/2016
Primary completion :
12/01/2037
Completion :
12/01/2037
CD22
|
CD22 expression
|
CART22
Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL) (NCT05010564)
Phase 1
Baylor College of Medicine
Baylor College of Medicine
Recruiting
Phase 1
Baylor College of Medicine
Recruiting
Last update posted :
02/02/2024
Initiation :
07/18/2023
Primary completion :
07/17/2026
Completion :
03/29/2040
CD20 • CD19 • CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • fludarabine IV • autologous TriCAR T • cyclophosphamide intravenous
Co-administration of CART22-65s and huCART19 for B-ALL (NCT05674175)
Phase 1/2
Stephan Grupp MD PhD
Stephan Grupp MD PhD
Recruiting
Phase 1/2
Stephan Grupp MD PhD
Recruiting
Last update posted :
12/19/2023
Initiation :
01/25/2023
Primary completion :
01/15/2027
Completion :
01/15/2029
CD22
|
CD19 expression • CD22 expression
|
Kymriah (tisagenlecleucel-T) • CART22 • huCART19
A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients (NCT06087419)
Phase 1/2
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Disease...
Not yet recruiting
Phase 1/2
Institute of Hematology & Blood Diseases Hospit...
Not yet recruiting
Last update posted :
11/02/2023
Initiation :
10/30/2023
Primary completion :
12/30/2024
Completion :
12/30/2025
CD22
|
CD22 expression
|
Venclexta (venetoclax) • Gazyva (obinutuzumab) • Besponsa (inotuzumab ozogamicin) • Epidaza (chidamide)
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) (NCT04150497)
Phase 1/2
Cellectis S.A.
Cellectis S.A.
Recruiting
Phase 1/2
Cellectis S.A.
Recruiting
Last update posted :
09/25/2023
Initiation :
10/14/2019
Primary completion :
12/31/2023
Completion :
01/31/2026
CD22
|
CD22 expression
|
Campath (alemtuzumab) • UCART22
Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL (EWALL-INO) (NCT03249870)
Phase 2
Versailles Hospital
Versailles Hospital
Active, not recruiting
Phase 2
Versailles Hospital
Active, not recruiting
Last update posted :
09/06/2023
Initiation :
12/28/2017
Primary completion :
05/30/2023
Completion :
06/01/2024
ABL1 • BCR • CD22
|
CD22 expression
|
Besponsa (inotuzumab ozogamicin)
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) (NCT04747912)
Phase 2
University of Chicago
University of Chicago
Recruiting
Phase 2
University of Chicago
Recruiting
Last update posted :
08/25/2023
Initiation :
03/02/2021
Primary completion :
06/30/2024
Completion :
05/01/2026
ABL1 • BCR • CD22
|
CD22 expression
|
dasatinib • Iclusig (ponatinib) • Besponsa (inotuzumab ozogamicin) • vincristine
Study of Sequential CAR-T Cell Treating Leukemia Children (NCT04340154)
Phase 2
Beijing Boren Hospital
Beijing Boren Hospital
Active, not recruiting
Phase 2
Beijing Boren Hospital
Active, not recruiting
Last update posted :
08/02/2023
Initiation :
05/01/2020
Primary completion :
05/01/2024
Completion :
11/01/2024
ABL1 • CD22
|
CD19 expression • CD22 positive • CD22 expression
|
cyclophosphamide
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (NCT03991884)
Phase 1
University of Washington
University of Washington
Completed
Phase 1
University of Washington
Completed
Last update posted :
07/06/2023
Initiation :
09/24/2019
Primary completion :
10/20/2022
Completion :
06/28/2023
CD22
|
CD22 positive • CD22 expression
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • daunorubicin • cyclophosphamide intravenous
Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma (NCT04648475)
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Recruiting
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
04/18/2023
Initiation :
08/25/2020
Primary completion :
12/31/2023
Completion :
07/01/2024
IL6 • CD22 • IL10
|
CD19 expression • CD22 positive • CD22 expression • IL10 elevation
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma (NCT04782193)
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Recruiting
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
04/18/2023
Initiation :
05/23/2021
Primary completion :
12/31/2023
Completion :
07/01/2024
IL6 • CD22 • IL10
|
CD19 expression • CD22 positive • CD22 expression • IL10 elevation
|
CD19 and CD22 targeted prime CAR-T
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma (NCT04649983)
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Chongqing Precision Biotech Co., Ltd
Recruiting
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
04/18/2023
Initiation :
09/01/2019
Primary completion :
12/31/2023
Completion :
07/01/2024
CD22
|
CD19 expression • CD22 positive • CD22 expression
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL (NCT04499573)
Phase 1/2
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Federal Research Institute of Pediatric...
Active, not recruiting
Phase 1/2
Federal Research Institute of Pediatric Hematol...
Active, not recruiting
Last update posted :
02/22/2023
Initiation :
07/27/2020
Primary completion :
03/13/2022
Completion :
03/13/2027
CD22
|
CD19 expression • CD22 expression
|
cytarabine • cyclophosphamide • etoposide IV • dexamethasone • fludarabine IV • Actemra IV (tocilizumab) • MB-CAR-T19-22
CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia (NCT05168748)
Phase 1
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Withdrawn
Phase 1
Novartis Pharmaceuticals
Withdrawn
Last update posted :
12/21/2022
Initiation :
01/24/2023
Primary completion :
08/13/2026
Completion :
08/13/2026
CD22
|
CD19 expression • CD22 expression
|
IMJ995
Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma (NCT05651100)
Phase 1/2
Kecellitics Biotech Company Ltd
Kecellitics Biotech Company Ltd
Not yet recruiting
Phase 1/2
Kecellitics Biotech Company Ltd
Not yet recruiting
Last update posted :
12/14/2022
Initiation :
12/10/2022
Primary completion :
12/10/2024
Completion :
12/10/2025
CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • CD19/CD22 chimeric antigen receptor T cell
Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL (INITIAL-1) (NCT03460522)
Phase 2
Nicola Goekbuget
Nicola Goekbuget
Recruiting
Phase 2
Nicola Goekbuget
Recruiting
Last update posted :
11/02/2022
Initiation :
05/02/2018
Primary completion :
06/01/2025
Completion :
12/01/2025
CD22
|
CD22 expression
|
Besponsa (inotuzumab ozogamicin)
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive (NCT05603156)
Phase N/A
Institute of Hematology & Blood Diseases Hospital
Institute of Hematology & Blood Disease...
Not yet recruiting
Phase N/A
Institute of Hematology & Blood Diseases Hospital
Not yet recruiting
Last update posted :
11/02/2022
Initiation :
10/30/2022
Primary completion :
07/31/2024
Completion :
07/31/2024
ABL1 • BCR • CD22
|
CD22 expression
|
Besponsa (inotuzumab ozogamicin) • Nailike (olverembatinib)
Study of Anti-CD22 CAR-T Cells Treating Leukemia Children (NCT04340167)
Phase 2
Beijing Boren Hospital
Beijing Boren Hospital
Recruiting
Phase 2
Beijing Boren Hospital
Recruiting
Last update posted :
08/15/2022
Initiation :
05/01/2020
Primary completion :
05/01/2024
Completion :
10/01/2024
ABL1 • CD22
|
CD22 positive • CD22 expression
|
cyclophosphamide • Anti-CD22 CAR-T Cells
CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) (NCT04034446)
Phase 1
Institute of Hematology & Blood Diseases Hospital
Institute of Hematology & Blood Disease...
Active, not recruiting
Phase 1
Institute of Hematology & Blood Diseases Hospital
Active, not recruiting
Last update posted :
08/03/2022
Initiation :
09/30/2019
Primary completion :
12/01/2023
Completion :
12/01/2023
CD22
|
CD22 expression
|
HY004
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) (AMELIA) (NCT03289455)
Phase 1/2
Autolus Limited
Autolus Limited
Completed
Phase 1/2
Autolus Limited
Completed
Last update posted :
02/01/2021
Initiation :
06/26/2017
Primary completion :
05/18/2020
Completion :
05/18/2020
CD22
|
CD19 expression • CD22 expression
|
cyclophosphamide • AUTO3
Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia (NCT04723901)
Phase 1/2
Shenzhen University General Hospital
Shenzhen University General Hospital
Recruiting
Phase 1/2
Shenzhen University General Hospital
Recruiting
Last update posted :
01/26/2021
Initiation :
10/20/2020
Primary completion :
12/31/2022
Completion :
12/31/2022
CD19 • CD22
|
CD19 expression • CD22 expression • CD19 underexpression
|
CD19/CD22 dual-target CAR-T
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL (NCT04412174)
Phase 1
Hebei Yanda Ludaopei Hospital
Hebei Yanda Ludaopei Hospital
Not yet recruiting
Phase 1
Hebei Yanda Ludaopei Hospital
Not yet recruiting
Last update posted :
06/02/2020
Initiation :
06/01/2020
Primary completion :
12/01/2022
Completion :
12/01/2022
CD22
|
CD22 positive • CD22 expression • CD20 negative
|
GC022F • SENL-B19
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL (NCT04129099)
Phase 1
Hebei Yanda Ludaopei Hospital
Hebei Yanda Ludaopei Hospital
Unknown status
Phase 1
Hebei Yanda Ludaopei Hospital
Unknown status
Last update posted :
05/28/2020
Initiation :
10/22/2019
Primary completion :
09/01/2020
Completion :
06/01/2022
CD22
|
CD19 expression • CD22 expression
|
GC022F • SENL-B19
Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL (NCT04163575)
Phase 1/2
Kecellitics Biotech Company Ltd
Kecellitics Biotech Company Ltd
Unknown status
Phase 1/2
Kecellitics Biotech Company Ltd
Unknown status
Last update posted :
12/23/2019
Initiation :
02/01/2020
Primary completion :
07/01/2021
Completion :
07/01/2022
CD22
|
CD22 expression
|
anti-CD22-CAR
A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies (NCT02935153)
Phase 1/2
Southwest Hospital, China
Southwest Hospital, China
Unknown status
Phase 1/2
Southwest Hospital, China
Unknown status
Last update posted :
06/25/2019
Initiation :
10/01/2016
Primary completion :
10/01/2019
Completion :
10/01/2020
CD22
|
CD22 expression
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login